Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Memorial Sloan Kettering Cancer Center
With
National Institutes of Health (NIH)
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Biopsy proven HER2-positive or HER2-low primary malignancy or metastatic disease
Note: HER2 positivity is defined according to American Society of Clinical Oncology guidelines or ERBB2 amplification on next generation sequencing Note: HER2-low is defined as low HER2 expression, with immunohistochemistry (IHC) 1+ or IHC 2+ and in situ hybridization \[ISH\]-negative, including FISH.
Biopsy proven primary malignancy or metastatic disease
At least one malignant lesion on CT, MR, or FDG PET/CT within 60 days of protocol enrollment
Age 18 years or greater
ECOG performance of 0-2
You may not be if
Creatinine \> 2 times normal limit (obtained with 8 weeks of enrollment)
AST/ALT \> 2 times normal limit (obtained with 8 weeks of enrollment)
Life expectancy \< 3 months
Pregnancy or lactation
Patients who cannot undergo PET/CT due to weight limits (over 450 pounds)
Clareo Health | Testing a New Imaging Agent to Identify Cancer
